In 2012, AbbVie's (ABBV 0.42%) Humira brought in $9.3 billion in total sales and was the best selling drug in the world. But did the autoimmune disease drug, which accounts for more than half of AbbVie's sales, keep its crown in 2013?
In the following slideshow, we reveal last year's three best-selling drugs. Blockbusters from powerhouses Amgen (AMGN -0.75%), Pfizer (PFE -0.37%), Johnson & Johnson (JNJ), and Merck (MRK -0.29%) all made the list.
Max Macaluso, Ph.D., has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
